An epidermal stem cell in vitro culture kit and its application
By optimizing the culture medium components, providing adhesion-promoting and conversion-promoting culture media, the complex and cost-effective operation of epidermal stem cells in in vitro culture is solved, and the preparation and simple operation of cells with high purity and strong proliferation ability are achieved, with broad application prospects .
Patent Information
- Application Number
- CN202111484594.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-07
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2041-12-07
AI Technical Summary
In the prior art, the in vitro culture method of epidermal stem cells is complex in operation and high in cost, making it difficult to obtain high-purity epidermal stem cells and maintain their proliferation ability.
By optimizing the culture medium components, it provides pro-adhesion culture medium and pro-transformation culture medium, including specific concentrations of cytokines and supplements, promotes cell adherence and transformation, reduces dependence on feeder cells, and reduces production costs.
The preparation of epidermal stem cells with high purity and strong proliferation ability is simple to operate, reduces production costs, and does not require flow sorting, and has broad application prospects.
Smart Images

Figure BDA0003397003240000121
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of cell biology, and in particular relates to an epidermal stem cell in vitro culture kit and application thereof. Background Art
[0002] Epidermal stem cells (ESCs) are a type of cell population that has the ability to proliferate and differentiate into various functional cells in the epidermis. They are mainly located in the basal layer of the epidermis, belong to adult stem cells, have strong division and proliferation capabilities, and can replenish aging and shed keratinocytes.
[0003] Epidermal stem cells, as skin tissue-specific stem cells, not only maintain the daily metabolism of the epidermis, but also actively participate in the repair of skin damage. It is of great significance to explore the proliferation, differentiation and migration of epidermal stem cells. Therefore, obtaining and culturing epidermal stem cells in vitro is the basis of related research work. At present, the conventional method is to obtain epidermal stem cells by primary culture of epidermal tissue, but this method is complicated to operate and requires cell sorting, which requires a high level of technical personnel; the obtained epidermal stem cells need to use feeder layer cells during culture, which is costly and not conducive to large-scale preparation.
[0004] How to obtain high-purity epidermal stem cells and maintain their stem cell phenotype and in vitro proliferation ability is an urgent problem to be solved in the in vitro culture of epidermal stem cells. Therefore, how to provide a method for obtaining and culturing epidermal stem cells with simple operation and low production cost has become an urgent problem to be solved. Summary of the invention
[0005] In view of the deficiencies of the prior art and actual needs, the present invention provides an epidermal stem cell in vitro culture kit and its application. By optimizing the components of the culture medium, cell adhesion can be promoted and the cell transformation efficiency can be improved. The prepared epidermal stem cells have high purity and strong in vitro proliferation ability, and are simple to operate without the need for flow cytometry.
[0006] To achieve this object, the present invention adopts the following technical solutions:
[0007] In a first aspect, the present invention provides an epidermal stem cell in vitro culture kit, the epidermal stem cell in vitro culture kit comprising an adhesion-promoting medium and a transformation-promoting medium;
[0008] The adhesion promoting medium comprises stem cell culture medium, cell culture supplement, fetal bovine serum, adhesion promoting cytokine and IL-3, wherein the concentration of IL-3 is 80-120 ng / mL, for example, it can be 80 ng / mL, 85 ng / mL, 90 ng / mL, 95 ng / mL, 100 ng / mL, 105 ng / mL, 110 ng / mL, 115 ng / mL or 120 ng / mL, and other specific point values within the numerical range can be selected, which will not be described one by one here;
[0009] The transformation-promoting medium includes stem cell culture medium, cell culture supplements, transformation-promoting cytokines, fibronectin and IL-3, wherein the concentration of IL-3 is 40 to 80 ng / mL, for example, it can be 40 ng / mL, 45 ng / mL, 50 ng / mL, 55 ng / mL, 60 ng / mL, 65 ng / mL, 70 ng / mL, 75 ng / mL or 80 ng / mL, and other specific point values within this numerical range can be selected, which will not be repeated here.
[0010] In the present invention, by optimizing the components of the culture medium, the adhesion-promoting culture medium has a higher effect on promoting cell adhesion, and the transformation-promoting culture medium has a higher efficiency in promoting cell transformation. The epidermal stem cells prepared after culture are larger in number, better in purity, and stronger in proliferation ability. No feeder layer cells are required during the culture process, which reduces production costs and has broad application prospects.
[0011] Preferably, the volume fraction of the cell culture supplement in the adhesion promoting medium is 1% to 10%, for example, it can be 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10%, etc. Other specific point values within this numerical range can be selected and will not be described one by one here.
[0012] Preferably, the volume fraction of the fetal bovine serum in the adhesion promoting medium is 1% to 10%, for example, it can be 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10%, etc. Other specific point values within this numerical range can be selected and will not be described here one by one.
[0013] Preferably, the adhesion promoting cytokines include rhGM-CSF, bFGF and SCF.
[0014] Preferably, the concentration of the rhGM-CSF in the adhesion promoting medium is 800-1200 IU / mL, for example, it can be 800 IU / mL, 850 IU / mL, 900 IU / mL, 950 IU / mL, 1000 IU / mL, 1050 IU / mL, 1100 IU / mL, 1150 IU / mL or 1200 IU / mL, etc. Other specific point values within this numerical range can be selected, which will not be described one by one here.
[0015] Preferably, the concentration of bFGF in the adhesion promoting medium is 80-120 ng / mL, for example, it can be 80 ng / mL, 85 ng / mL, 90 ng / mL, 95 ng / mL, 100 ng / mL, 105 ng / mL, 110 ng / mL, 115 ng / mL or 120 ng / mL, etc. Other specific point values within this numerical range can be selected and will not be described one by one here.
[0016] Preferably, the concentration of the SCF in the adhesion promoting medium is 80-120 ng / mL, for example, it can be 80 ng / mL, 85 ng / mL, 90 ng / mL, 95 ng / mL, 100 ng / mL, 105 ng / mL, 110 ng / mL, 115 ng / mL or 120 ng / mL, etc. Other specific point values within this numerical range can be selected and will not be described one by one here.
[0017] Preferably, the volume fraction of the cell culture supplement in the transformation-promoting medium is 1% to 10%, for example, it can be 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10%, etc. Other specific point values within this numerical range can be selected and will not be described one by one here.
[0018] Preferably, the concentration of the fibronectin in the transformation-promoting medium is 40-80 μg / mL, for example, it can be 40 μg / mL, 45 μg / mL, 50 μg / mL, 55 μg / mL, 60 μg / mL, 65 μg / mL, 70 μg / mL, 75 μg / mL or 80 μg / mL, and other specific point values within this numerical range can be selected, which will not be described here one by one.
[0019] Preferably, the transformation-promoting cytokines include EGF and BPE.
[0020] Preferably, the concentration of EGF in the transformation-promoting medium is 40-80 IU / mL, for example, it can be 40 IU / mL, 45 IU / mL, 50 IU / mL, 55 IU / mL, 60 IU / mL, 65 IU / mL, 70 IU / mL, 75 IU / mL or 80 IU / mL, and other specific point values within this numerical range can be selected, which will not be described one by one here.
[0021] Preferably, the concentration of BPE in the transformation-promoting medium is 40-80 μg / mL, for example, it can be 40 μg / mL, 45 μg / mL, 50 μg / mL, 55 μg / mL, 60 μg / mL, 65 μg / mL, 70 μg / mL, 75 μg / mL or 80 μg / mL, etc. Other specific point values within this numerical range can be selected, and they will not be described one by one here.
[0022] As a preferred technical solution, the epidermal stem cell in vitro culture kit of the present invention comprises an adhesion-promoting medium and a transformation-promoting medium;
[0023] The adhesion promoting medium comprises, by volume fraction, 1% to 10% of a cell culture supplement, 1% to 10% of fetal bovine serum, 800 to 1200 IU / mL of rhGM-CSF, 80 to 120 ng / mL of bFGF, 80 to 120 ng / mL of SCF and 80 to 120 ng / mL of IL-3, and the remainder is a stem cell culture medium;
[0024] Calculated by volume fraction, the transformation-promoting medium includes 1% to 10% cell culture supplement, 40 to 80 IU / mL of EGF, 40 to 80 μg / mL of BPE, 40 to 80 μg / mL of fibronectin and 40 to 80 ng / mL of IL-3, and the remainder is stem cell culture medium.
[0025] In a second aspect, the present invention provides a method for culturing epidermal stem cells in vitro, the method comprising:
[0026] Wash and disinfect the umbilical cord tissue, remove the Wharton colloid, cut it into pieces, and collect the tissue blocks by centrifugation;
[0027] The cells are cultured for 3 to 6 days using the adhesion-promoting medium described in the first aspect to promote cell adhesion. The culture time can be, for example, 3 days, 3.5 days, 4 days, 4.5 days, 5 days, 5.5 days or 6 days, and other specific values within this numerical range can be selected, which will not be described in detail here;
[0028] The adherent cells are subcultured for 4 to 8 days using the transformation-promoting medium described in the first aspect, and the cells are collected to obtain the epidermal stem cells. The culture time can be, for example, 4 days, 4.5 days, 5 days, 5.5 days, 6 days, 6.5 days, 7 days, 7.5 days or 8 days, and other specific point values within this numerical range can be selected, which will not be described here one by one.
[0029] In the present invention, the culture method is simple to operate, does not require flow sorting, does not require tissue lysis, and does not require obtaining one's own tissue for primary culture. It has low technical requirements for operators and high culture efficiency. No feeder layer cells are required during the culture process, and the cost is low.
[0030] Preferably, the step of promoting cell adhesion further includes removing semi-adherent cells.
[0031] Preferably, before the subculture, the cell adhesion rate is not less than 50%, for example, it can be 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%, etc. Other specific point values within this numerical range can be selected and will not be described here one by one.
[0032] Preferably, during the subculture, the cell adhesion rate is not less than 80%, for example, it can be 80%, 85%, 90% or 95%, etc. Other specific point values within this numerical range can be selected and will not be described in detail here.
[0033] Preferably, the number of subcultures is 2 to 4 times, for example, 2 times, 3 times or 4 times.
[0034] Preferably, the step of quality control testing is also included before collecting cells.
[0035] As a preferred technical solution, the method for culturing epidermal stem cells in vitro of the present invention comprises the following steps:
[0036] Wash and disinfect the umbilical cord tissue, remove the Wharton colloid, cut it into pieces, and collect the tissue blocks by centrifugation;
[0037] Cultivating the tissue block for 3 to 6 days using the adhesion-promoting medium described in the first aspect to promote cell adhesion and remove semi-adherent cells;
[0038] When the cell adhesion rate is not less than 50%, the adherent cells are subcultured for 4 to 8 days using the transformation-promoting medium described in the first aspect. During the subculture, the cell adhesion rate is not less than 80%. The cells are subcultured 2 to 4 times. After quality control testing, the cells are collected to obtain the epidermal stem cells.
[0039] In a third aspect, the present invention provides an epidermal stem cell, which is cultured by the epidermal stem cell in vitro culture method described in the second aspect.
[0040] In the present invention, the epidermal stem cells have high purity, good proliferation ability and broad application prospects.
[0041] In a fourth aspect, the present invention provides the use of any one or a combination of at least two of the epidermal stem cell in vitro culture kit described in the first aspect, the epidermal stem cell in vitro culture method described in the second aspect, or the epidermal stem cells described in the third aspect in the preparation of an anti-wrinkle injection.
[0042] In a fifth aspect, the present invention provides an anti-wrinkle injection, which contains the epidermal stem cells and injection according to the third aspect;
[0043] The injection comprises sodium chloride solution, astragalus injection, human serum albumin, cytokines and recombinant proteins;
[0044] The density of the epidermal stem cells in the anti-wrinkle injection is (1-5)×10 8 / mL, for example, 1×10 8 / mL, 1.5×10 8 / mL, 2×10 8 / mL, 2.5×10 8 / mL, 3×10 8 / mL, 3.5×10 8 / mL, 4×10 8 / mL, 4.5×10 8 / mL or 5×10 8 Pieces / mL, etc. Other specific point values within this numerical range can be selected and will not be described here one by one.
[0045] In the present invention, the anti-wrinkle injection contains epidermal stem cells and factors that promote cell proliferation and division, and has a highly effective anti-wrinkle effect; the anti-wrinkle injection can be directly injected for use, is easy to use, and has practical application value.
[0046] Preferably, the mass concentration of the sodium chloride solution is 0.7% to 0.9%, for example, it can be 0.7%, 0.75%, 0.8%, 0.85% or 0.9%, and other specific point values within this numerical range can be selected, which will not be described here one by one.
[0047] Preferably, the volume fraction of the Astragalus injection in the injection is 1% to 5%, for example, it can be 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5% or 5%, etc. Other specific point values within this numerical range can be selected and will not be described here one by one.
[0048] Preferably, the concentration of human serum albumin in the injection is 0.01-0.1 g / mL, for example, it can be 0.01 g / mL, 0.02 g / mL, 0.03 g / mL, 0.04 g / mL, 0.05 g / mL, 0.06 g / mL, 0.07 g / mL, 0.08 g / mL, 0.09 g / mL or 0.1 g / mL, etc. Other specific point values within this numerical range can be selected, which will not be described one by one here.
[0049] Preferably, the cytokine includes SCF, and the concentration of SCF in the injection solution is 5 to 9 ng / mL, for example, 5 ng / mL, 5.5 ng / mL, 6 ng / mL, 6.5 ng / mL, 7 ng / mL, 7.5 ng / mL, 8 ng / mL, 8.5 ng / mL or 9 ng / mL, etc. Other specific point values within this numerical range can be selected and will not be described one by one here.
[0050] Preferably, the recombinant protein includes Dnmt3a recombinant protein and Dnmt3b recombinant protein, and the concentration of the Dnmt3a recombinant protein and the Dnmt3b recombinant protein in the injection solution is 0.5-2 μg / mL, for example, 0.5 μg / mL, 1 μg / mL, 1.5 μg / mL or 2 μg / mL, etc. Other specific point values within this numerical range can be selected, and they will not be described one by one here.
[0051] As a preferred technical solution, the injection includes, by volume fraction, 1% to 5% astragalus injection, 0.01 to 0.1 g / mL human serum albumin, 5 to 9 ng / mL SCF, 0.5 to 2 μg / mL Dnmt3a recombinant protein and 0.5 to 2 μg / mL Dnmt3b recombinant protein, and the remainder is a sodium chloride solution with a mass concentration of 0.7% to 0.9%.
[0052] Compared with the prior art, the present invention has the following beneficial effects:
[0053] The invention optimizes the formula of the adhesion-promoting culture medium and the transformation-promoting culture medium, so that the cell adhesion rate and the transformation efficiency are significantly improved, and the epidermal stem cells that can be prepared efficiently and quickly are larger in number and have stronger proliferation ability; the invention performs directed induction transformation on umbilical cord Wharton's jelly mesenchymal stem cells, so that the prepared epidermal stem cells have high purity, do not need flow sorting, and are easy to operate; the epidermal stem cells have good transformation efficiency and strong proliferation ability, can promote cell proliferation and repair of skin damage; do not need feeder layer cells during cultivation, and have low cost; do not need to obtain their own tissues and tissue lysis, have low requirements on the operation level of technicians, and have high success rate; the anti-wrinkle injection contains epidermal stem cells and factors that promote cell proliferation and division, can promote cell division and proliferation in the dermis layer of the skin after injection, has obvious anti-wrinkle effect, can be directly injected for use, is convenient to use, and has broad application prospects. DETAILED DESCRIPTION
[0054] To further illustrate the technical means and effects of the present invention, the present invention is further described below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention, rather than to limit the present invention.
[0055] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0056] Material:
[0057] Stem cell culture medium and fetal bovine serum were purchased from Thermo Fisher Scientific (China) Co., Ltd.;
[0058] Cell culture supplements were purchased from Helios Bioscience;
[0059] IL-3, rhGM-CSF, bFGF, SCF, fibronectin, EGF, BPE, Dnmt3a recombinant protein, and Dnmt3b recombinant protein were purchased from HZbscience;
[0060] Astragalus injection was purchased from Shenwei Pharmaceutical Group Co., Ltd.;
[0061] Human serum albumin was purchased from Shanghai Laishi Blood Products Co., Ltd.;
[0062] CD49f+ antibody and CD71+ antibody were purchased from BD (China).
[0063] Example 1
[0064] This embodiment provides an epidermal stem cell in vitro culture kit, which includes an adhesion-promoting medium and a transformation-promoting medium;
[0065] The adhesion promoting medium comprises, by volume fraction, 8% cell culture supplement, 8% fetal bovine serum, 1000 IU / mL rhGM-CSF, 100 ng / mL bFGF, 100 ng / mL SCF and 100 ng / mL IL-3, and the remainder is stem cell culture medium;
[0066] Calculated by volume fraction, the transformation-promoting medium includes 8% cell culture supplement, 70 IU / mL EGF, 70 μg / mL BPE, 70 μg / mL fibronectin and 70 ng / mL IL-3, and the remainder is stem cell culture medium.
[0067] Example 2
[0068] This embodiment provides an epidermal stem cell in vitro culture kit, which includes an adhesion-promoting medium and a transformation-promoting medium;
[0069] The adhesion promoting medium comprises, by volume fraction, 10% cell culture supplement, 10% fetal bovine serum, 800 IU / mL of rhGM-CSF, 80 ng / mL of bFGF, 80 ng / mL of SCF and 80 ng / mL of IL-3, and the remainder is stem cell culture medium;
[0070] Calculated by volume fraction, the transformation-promoting medium includes 10% cell culture supplement, 40 IU / mL EGF, 40 μg / mL BPE, 40 μg / mL fibronectin and 40 ng / mL IL-3, and the remainder is stem cell culture medium.
[0071] Example 3
[0072] This embodiment provides an epidermal stem cell in vitro culture kit, which includes an adhesion-promoting medium and a transformation-promoting medium;
[0073] The adhesion promoting medium comprises, by volume fraction, 1% cell culture supplement, 1% fetal bovine serum, 1200 IU / mL of rhGM-CSF, 120 ng / mL of bFGF, 120 ng / mL of SCF and 120 ng / mL of IL-3, and the remainder is stem cell culture medium;
[0074] Calculated by volume fraction, the transformation-promoting medium includes 1% cell culture supplement, 80 IU / mL EGF, 80 μg / mL BPE, 80 μg / mL fibronectin and 80 ng / mL IL-3, and the remainder is stem cell culture medium.
[0075] Example 4
[0076] This embodiment provides an epidermal stem cell, which is cultured by the following method:
[0077] (1) Disinfect the operating table, reagents, and equipment before culture;
[0078] (2) Cleaning and disinfecting the umbilical cord tissue;
[0079] Wash the umbilical cord tissue twice with D-PBS solution, soak it in 75% alcohol solution for 20 seconds for disinfection; wash it twice with D-PBS solution, soak it in 75% alcohol solution again for 20 seconds; wash it once with D-PBS solution, place it in a clean culture dish containing D-PBS solution, and cut it into 2 cm small sections;
[0080] (3) Take out the Wharton colloid, cut it into pieces, and collect the tissue blocks by centrifugation:
[0081] The umbilical cord was placed in D-PBS solution with hemostats to wash away the blood, a small hole was cut with a scalpel, the umbilical cord was torn open and Wharton's colloid was extracted;
[0082] Wash the Wharton colloid with D-PBS solution and cut into 2×2cm 2 The small pieces were transferred to a centrifuge tube, centrifuged at 400 g for 10 min at room temperature, and the supernatant was removed to obtain tissue blocks;
[0083] (4) Promote cell adhesion:
[0084] The tissue block was inoculated into a T75 cell culture flask, 20 mL of the adhesion-promoting medium in Example 1 was added, and the cells were cultured at 37° C. and 5% carbon dioxide concentration for 3 days. During this period, the culture flask was not shaken to promote cell adhesion;
[0085] On the 4th day, slowly pour out the culture supernatant and remove the semi-adherent cells; add 20 mL of adhesion-promoting medium and continue culturing at 37°C and 5% carbon dioxide concentration;
[0086] On the 6th day, the cells were observed under a microscope. If the cell adhesion rate exceeded 50%, the culture supernatant was slowly poured out, the tissue blocks were removed, and 20 mL of the transformation-promoting medium in Example 1 was added, and the cells were cultured at 37° C. and 5% carbon dioxide concentration.
[0087] (5) Subculture:
[0088] On the eighth day, the cells were observed under a microscope. If the cell adhesion rate exceeded 80%, the cells were digested and subcultured. Each bottle contained 20 mL of transformation medium and cultured at 37°C and 5% carbon dioxide concentration.
[0089] On the 10th day, the cells were observed under a microscope. If the cell adhesion rate exceeded 80%, the cells were digested and subcultured. Each bottle contained 20 mL of transformation medium and cultured at 37°C and 5% carbon dioxide concentration.
[0090] On the 12th day, the cells were observed under a microscope. If the cell adhesion rate exceeded 80%, the cells were digested and subcultured. Each bottle contained 20 mL of transformation medium and cultured at 37°C and 5% carbon dioxide concentration.
[0091] (6) Collecting cells:
[0092] On the 14th day, the cells were digested and collected after quality control testing to obtain the epidermal stem cells.
[0093] Example 5
[0094] This embodiment provides an epidermal stem cell, which is cultured using the epidermal stem cell in vitro culture kit in Example 2, and the culture method is the same as that in Example 4.
[0095] Example 6
[0096] This embodiment provides an epidermal stem cell, which is cultured using the epidermal stem cell in vitro culture kit in Example 3, and the culture method is the same as that in Example 4.
[0097] The epidermal stem cells prepared in Examples 4 to 6 were subjected to flow cytometry detection in the following steps:
[0098] 1. Place the culture flask in a biosafety cabinet, use trypsin to digest until all cells fall off, use D-PBS to stop digestion, collect the cells, centrifuge at 400g for 5 minutes at room temperature, and resuspend the cells with 10mL D-PBS;
[0099] 2. Take about 1 million cells (about 200 μL) and place them in an EP tube, add 800 μL D-PBS, mix well, centrifuge at 400 g for 5 min at room temperature, discard the supernatant, and obtain the cells;
[0100] 3. Use 200 μL of D-PBS containing 5% FBS to mix the cells, and take 200 μL of the resuspension and place it in a new flow tube;
[0101] 4. Add 0.5 μL CD49f+ antibody and 0.5 μL CD71+ antibody to the flow tube in sequence;
[0102] 5. Mix on a vortex shaker for 20 seconds and stain at 4°C in the dark for 20 minutes;
[0103] 6. Log in and save the data;
[0104] 7. Analyze the data.
[0105] The test results are shown in Table 1.
[0106] Table 1
[0107]
[0108] As can be seen from Table 1, the cells prepared in Examples 4 to 6 all have good transformation efficiency, and the transformation promoting factor combination can achieve the transformation efficiency of the high concentration factor combination using a lower concentration. Comparing Example 6 with Example 4 and Example 5, it can be seen that the lower concentration factor combination has a more efficient transformation efficiency.
[0109] Example 7
[0110] This embodiment provides an anti-wrinkle injection, which contains epidermal stem cells cultured in Example 4 and an injection;
[0111] The density of the epidermal stem cells in the anti-wrinkle injection is 1×10 8 Pieces / mL;
[0112] Calculated by volume fraction, the injection includes 3% astragalus injection, 0.08 g / mL human serum albumin, 7 ng / mL SCF, 1.5 μg / mL Dnmt3a recombinant protein and 1.5 μg / mL Dnmt3b recombinant protein, and the remainder is a sodium chloride solution with a mass concentration of 0.8%.
[0113] Example 8
[0114] This embodiment provides an anti-wrinkle injection, which contains epidermal stem cells cultured in Example 5 and an injection;
[0115] The density of the epidermal stem cells in the anti-wrinkle injection is 1×10 8 Pieces / mL;
[0116] Calculated by volume fraction, the injection includes 5% astragalus injection, 0.1 g / mL human serum albumin, 9 ng / mL SCF, 2 μg / mL Dnmt3a recombinant protein and 2 μg / mL Dnmt3b recombinant protein, and the remainder is a sodium chloride solution with a mass concentration of 0.7%.
[0117] Example 9
[0118] This embodiment provides an anti-wrinkle injection, which contains epidermal stem cells cultured in Example 6 and an injection;
[0119] The density of the epidermal stem cells in the anti-wrinkle injection is 1×108 Pieces / mL;
[0120] Calculated by volume fraction, the injection includes 1% astragalus injection, 0.01g / mL human serum albumin, 5ng / mL SCF, 0.5μg / mL Dnmt3a recombinant protein and 0.5μg / mL Dnmt3b recombinant protein, and the balance is a sodium chloride solution with a mass concentration of 0.9%.
[0121] Example 10
[0122] This example uses the anti-wrinkle injection prepared in Examples 7 to 9 for injection, and the steps are as follows:
[0123] (1) Prepare iodine, cotton swabs, cotton balls and other items in advance, lay out disposable sterile surgical sheets, and sterilize the operating room with ultraviolet ozone for 30 minutes 40 minutes in advance. After the operation, use a ventilation device to purify the room air for 10 minutes.
[0124] (2) No anesthesia is required. Use iodine to wipe and disinfect the surface of the wrinkles, and then use 75% medical alcohol to further wipe and disinfect. Use a disposable sterile surgical marker to mark the beginning and end of the wrinkles, and mark every 4 mm between the beginning and the end as the injection point;
[0125] Rotate the disposable micro-syringe containing the anti-wrinkle injection solution so that the scale is facing upwards and the needle tip is facing downwards, mix the anti-wrinkle injection solution again, and empty the air in the syringe. With the needle tip facing downwards, place it close to the skin injection point and gently pierce the skin surface at about 45° to a depth of about 2mm. Inject 1 μL of anti-wrinkle injection solution into the skin surface, and then inject the anti-wrinkle injection solution into all marked points in a targeted and quantitative manner in turn.
[0126] (3) After the injection, do not wash your face, touch, press the injection site, or put on makeup within 48 hours.
[0127] According to instrumental analysis, facial wrinkles showed signs of fading one week after the injection of the anti-wrinkle injection prepared in Examples 7 to 9, and the injection site showed a natural luster. After two weeks, facial wrinkles were significantly reduced, and the injection site showed a natural luster and rosy color. In addition, no adverse reactions such as redness, swelling, itching, and immune rejection occurred, and the safety was guaranteed, which has practical application value.
[0128] In summary, the epidermal stem cell in vitro culture kit of the present invention optimizes the culture medium components and cooperates with the epidermal stem cell in vitro culture method of the present invention, so that the prepared epidermal stem cells have good proliferation and division ability and high purity, do not need flow sorting, do not need feeder layer cells to assist in culture, and are easy to operate; after being mixed with the injection solution, they are injected into the skin, can divide rapidly, have obvious anti-wrinkle effect, are easy to use, and have broad application prospects.
[0129] The applicant declares that the present invention illustrates the detailed method of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned detailed method, that is, it does not mean that the present invention must rely on the above-mentioned detailed method to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
Claims
1. A method for culturing epidermal stem cells in vitro, characterized in that: The method comprises: Wash and disinfect the umbilical cord tissue, remove the Wharton colloid, cut it into pieces, and collect the tissue blocks by centrifugation; Use adhesion-promoting medium to culture tissue pieces for 3 to 6 days to promote cell adhesion; Subculturing the adherent cells for 4 to 8 days using a transformation-promoting medium, collecting the cells, and obtaining the epidermal stem cells; The adhesion promoting medium comprises, by volume fraction, 1% to 10% of a cell culture supplement, 1% to 10% of fetal bovine serum, 800 to 1200 IU / mL of an adhesion promoting cytokine rhGM-CSF, 80 to 120 ng / mL of an adhesion promoting cytokine bFGF, 80 to 120 ng / mL of an adhesion promoting cytokine SCF, and 80 to 120 ng / mL of IL-3, and the remainder is a stem cell culture medium; The transformation-promoting medium comprises, by volume fraction, 1% to 10% of a cell culture supplement, 40 to 80 IU / mL of a transformation-promoting cytokine EGF, 40 to 80 μg / mL of a transformation-promoting cytokine BPE, 40 to 80 μg / mL of fibronectin, and 40 to 80 ng / mL of IL-3, and the remainder is a stem cell culture medium; Before the subculture, the cell adhesion rate is not less than 50%; during the subculture, the cell adhesion rate is not less than 80%; the number of subcultures is 2 to 4 times; The stem cell culture medium was purchased from Thermo Fisher Scientific China Co., Ltd., and the cell culture supplement was purchased from Helios Bioscience.
2. The method for culturing epidermal stem cells in vitro according to claim 1, characterized in that: The step of promoting cell adhesion also includes removing semi-adherent cells.
3. The method for culturing epidermal stem cells in vitro according to claim 1, characterized in that: The method also includes a quality control test step before collecting cells.
4. The method for culturing epidermal stem cells in vitro according to claim 1, characterized in that: The method comprises: Wash and disinfect the umbilical cord tissue, remove the Wharton colloid, cut it into pieces, and collect the tissue blocks by centrifugation; Use adhesion-promoting medium to culture tissue pieces for 3-6 days to promote cell adhesion and remove semi-adherent cells; When the cell adhesion rate is not less than 50%, the adherent cells are subcultured for 4 to 8 days using a transformation-promoting medium. During the subculture, the cell adhesion rate is not less than 80%. The cells are subcultured 2 to 4 times. After quality control testing, the cells are collected to obtain the epidermal stem cells.
5. Use of the method for culturing epidermal stem cells in vitro according to any one of claims 1 to 4 in the preparation of anti-wrinkle injection.
